01OverviewDefinition, clinical context and the essential points that orientate the chapter.
DLB is a synucleinopathy with cognitive decline and a characteristic combination of network fluctuation, visual processing dysfunction, hallucinations, sleep disorder and parkinsonism. Visual hallucinations are often detailed people or animals and may initially be recognised as unreal. Misidentification, passage hallucinations and visuospatial errors can coexist. Fluctuations may resemble staring, daytime somnolence or episodes of disorganised speech, but any new acute deterioration still requires a delirium search.
REM sleep behaviour disorder reflects loss of normal muscle atonia during dreaming and may precede dementia by years. Parkinsonism may be relatively symmetric, with rigidity, bradykinesia and gait disturbance; tremor is not essential. Autonomic involvement causes orthostatic hypotension, constipation, urinary dysfunction, sexual dysfunction and temperature or sweating problems. Antipsychotic sensitivity ranges from marked motor worsening and sedation to life-threatening rigidity and autonomic collapse.
Diagnosis is clinical, supported where needed by dopaminergic SPECT, polysomnographic confirmation of REM sleep without atonia or other specialist biomarkers. Mixed Alzheimer pathology is common and can make memory loss more prominent. Cognitive, sleep and orthostatic treatments, and any antipsychotic use, require individual specialist assessment and local shared-care governance.
Key points
- Core clinical features are marked cognitive fluctuation, recurrent well-formed visual hallucinations, REM sleep behaviour disorder and spontaneous parkinsonism.
- Early cognition often emphasises attention, executive and visuoperceptual dysfunction; prominent storage-memory loss may be less striking than in typical Alzheimer disease.
- Fluctuation means spontaneous variation in attention and alertness over minutes, hours or days, not simply good and bad months or delirium during infection.
- Ask about dream enactment years before cognitive diagnosis, including shouting, punching, falling from bed and injury to the person or bed partner.
- Supportive features include repeated falls, syncope, severe autonomic dysfunction, depression, apathy, hyposmia and marked sensitivity to dopamine-blocking antipsychotics.
- When parkinsonism begins before or within about one year of dementia, the clinical label is DLB; dementia arising after established Parkinson disease is termed Parkinson disease dementia.
- If clinical diagnosis remains uncertain, NICE recommends iodine-123 FP-CIT SPECT to assess striatal dopaminergic transporter uptake, while a normal scan does not absolutely exclude DLB.
- Offer donepezil or rivastigmine for mild to moderate DLB; these medicines may help cognition, fluctuation and hallucinations, with pulse, syncope, weight and gastrointestinal monitoring.
- Avoid antipsychotics whenever possible because they can worsen motor and cognitive symptoms and cause severe sensitivity; if risk or severe distress leaves no alternative, use specialist-led lowest exposure and frequent review.
- Levodopa may modestly improve disabling parkinsonism but can worsen hallucinations and confusion, so treatment goals and dose increments should be conservative.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Lewy-body neurodegeneration
DLB is a synucleinopathy associated with cognitive decline, fluctuating attention, visual hallucinations, REM sleep behaviour disorder, parkinsonism and autonomic involvement.
Mixed Alzheimer pathology
Alzheimer pathology commonly coexists with DLB and can make memory loss more prominent, altering the clinical profile and diagnostic certainty.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Lewy-body accumulation
Misfolded alpha-synuclein accumulates within neurons and synapses, disrupting signalling across arousal, visual, motor, sleep and autonomic systems.
- 2Visual and motor system dysfunction
Disrupted visual-association and nigrostriatal systems produce visuospatial errors, recurrent formed hallucinations, bradykinesia, rigidity and gait impairment during disease progression.
- 3Distributed network fluctuation
Variable network efficiency produces marked changes in alertness and cognition, recurrent visual hallucinations and REM sleep without normal muscle atonia.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Unexpected shifts between coherent alert engagement and pronounced drowsiness, staring or disorganised thought over short periods are characteristic after delirium and medicines are excluded.
Recurrent detailed images of people, children or animals, often with retained partial insight early, carry more diagnostic weight than vague shadows or isolated bereavement experiences.
Dream enactment with vocalisation and complex limb movement during sleep, especially with injury risk, supports synucleinopathy and may long predate daytime cognitive symptoms.
Bradykinesia, rigidity and gait dysfunction not explained by dopamine-blocking drugs provide a core feature even when classic pill-rolling tremor is absent.
Disproportionate sedation, confusion, immobility, rigidity, swallowing decline or autonomic instability after an antipsychotic is a major warning and may require emergency treatment.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Patient and informant core-feature historyFirst step - Why
- Establish fluctuation, hallucinations, dream enactment, parkinsonism and their temporal relationship to cognitive decline.
- Interpretation and limitations
- Use concrete examples and separate chronic fluctuation from acute delirium. Ask a bed partner about dream behaviour and review dopamine-blocking medicines before calling parkinsonism spontaneous.
- 02
Domain-based cognitive and neurological examination - Why
- Identify attention, executive, visuoperceptual and motor features typical of DLB.
- Interpretation and limitations
- Clock, visual search and executive tasks may be disproportionately affected. Repeated measurement can vary with fluctuation, so one low or high score should not dominate the formulation.
- 03
MRI or CT brain - Why
- Exclude structural disease, evaluate vascular or Alzheimer co-pathology and support a dementia work-up.
- Interpretation and limitations
- Relative preservation of medial temporal structures may support DLB compared with Alzheimer disease but is neither sensitive nor specific enough to diagnose it alone.
- 04
Iodine-123 FP-CIT SPECT - Why
- Demonstrate reduced striatal dopaminergic transporter uptake when DLB is suspected but clinical diagnosis remains uncertain.
- Interpretation and limitations
- Reduced uptake supports a Lewy body disorder after drug and technical factors are considered. NICE advises that a normal result should not be used as absolute exclusion when the phenotype remains convincing.
- 05
Polysomnography or sleep assessment - Why
- Confirm REM sleep without atonia and assess injuries or alternative sleep disorders when history is uncertain.
- Interpretation and limitations
- Documented REM sleep without atonia is an indicative biomarker, but obstructive sleep apnoea, periodic movements and medication effects may coexist and require their own treatment.
- 06
Orthostatic observations and autonomic review - Why
- Identify treatable contributors to falls, syncope, cognitive fluctuation and medication intolerance.
- Interpretation and limitations
- Measure supine and standing blood pressure and pulse with symptoms, then review hydration, meals and hypotensive or anticholinergic medicines before adding pressor treatment.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Alzheimer disease
Early storage-memory failure without hallucinations, marked fluctuation, REM sleep behaviour disorder or parkinsonism favours typical Alzheimer disease, though mixed pathology is common.
Parkinson disease dementia
Dementia beginning after well-established Parkinson disease is labelled Parkinson disease dementia; cognitive decline before or near motor onset supports DLB.
Delirium
Acute hours-to-days fluctuation from infection, pain or medicines indicates delirium, which can coexist with and be amplified by underlying DLB.
Atypical parkinsonism
Early severe autonomic failure, stridor, gaze palsy or recurrent falls may favour multiple-system atrophy or progressive supranuclear palsy over DLB.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01SuspectBuild a core-feature chronologyFirst stepDementia presents with visual, fluctuation, motor or sleep features.+
- 11. Obtain patient and collateral descriptions of hallucinations, short-timescale alertness variation, dream enactment and motor change, documenting onset relative to dementia.
- 22. Review antipsychotic, antiemetic, sedative and dopaminergic exposures and exclude delirium, eye disease, sleep apnoea and vascular mimics.
- 33. Examine cognition by domain, eye movements, bradykinesia, rigidity, gait and orthostatic physiology and arrange structural imaging and routine dementia bloods.
- 44. If uncertainty remains clinically important, request FP-CIT SPECT or sleep testing through the specialist memory or movement service.
02TreatImprove cognition without destabilising physiologyDLB diagnosis is sufficiently established and symptoms affect daily life.+
- 11. Review pulse, ECG indications, syncope, weight, gastrointestinal symptoms and anticholinergic burden before offering donepezil or rivastigmine.
- 22. Titrate the selected cholinesterase inhibitor slowly and assess cognition, fluctuation, hallucinations and function with carer observations.
- 33. If inhibitors are contraindicated or not tolerated, consider memantine through the specialist pathway; treat motor symptoms with cautious levodopa only when disability warrants it.
- 44. Address orthostasis, constipation, urinary dysfunction, sleep safety, falls and swallowing using non-drug and multidisciplinary measures before adding interacting medicines.
03Distress or psychosisAvoid reflex dopamine blockadeHallucinations, delusions or agitation become distressing or create risk.+
- 11. Determine whether hallucinations are distressing and search for delirium, pain, infection, vision loss, sleep disruption, environment and medicine causes.
- 22. Optimise cholinesterase treatment and use reassurance, lighting, familiar routine and carer strategies when safety permits.
- 33. If severe distress or risk persists, obtain older-adult psychiatry and DLB-experienced advice before the lowest-risk, lowest-dose, shortest antipsychotic trial.
- 44. Monitor after every dose for sedation, rigidity, swallowing, falls, cognition, temperature and autonomic change and stop urgently if severe sensitivity develops.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Rivastigmine
Start 1.5 mg orally twice daily with food and increase no more often than every two weeks towards the lowest helpful tolerated dose; a transdermal pathway may suit selected adherence or gastrointestinal problems.Monitor nausea, diarrhoea, weight loss, bradycardia, syncope, falls and tremor. Check patch technique and remove the old patch before a new one; restart low after a significant interruption.
Levodopa for disabling parkinsonism
A specialist may begin a low levodopa combination dose, such as co-beneldopa 12.5/50 mg once to three times daily, and increase slowly against a defined mobility goal.Monitor hallucinations, confusion, orthostatic hypotension, nausea and dyskinesia. Avoid chasing a normal motor examination with high doses, and never stop established dopaminergic therapy abruptly.
Antipsychotic only under exceptional specialist review
If severe distress or risk persists after cause and non-drug work, use the specialist-selected agent at the smallest starting dose for the shortest period with review at least every six weeks and often sooner.Haloperidol and potent dopamine blockade can cause catastrophic worsening. Explain stroke and mortality risk, monitor rigidity, consciousness, swallowing and autonomic state after every change, and stop if benefit is absent.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Falls, syncope and injury
Parkinsonism, visual misperception and autonomic hypotension combine to cause recurrent falls, collapse, fractures and loss of mobility.
Severe antipsychotic sensitivity
Dopamine blockade can provoke profound rigidity, sedation, autonomic collapse or neuroleptic malignant syndrome, making behavioural prescribing unusually hazardous.
Dysphagia and autonomic morbidity
Progressive swallowing, bladder, bowel and blood-pressure dysfunction causes aspiration, infection, constipation, malnutrition and substantial care dependence.
Behavioural and carer burden
Hallucinations, sleep disturbance and cognitive fluctuation can be frightening and unpredictable, increasing safeguarding concerns and sustained strain on families.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Track fluctuation, visual hallucinations, sleep enactment, cognition and daily function with informant observations rather than interpreting one clinic-day performance as stable baseline.
- Measure pulse, weight, syncope, gastrointestinal tolerance and falls after cholinesterase inhibitor initiation and each dose increment.
- Check supine and standing blood pressure, hydration, constipation, urinary symptoms and hypotensive medicines when falls or cognition vary.
- Review levodopa against a specific walking, transfer or rigidity goal while monitoring psychosis, confusion and orthostasis.
- During any antipsychotic exposure, reassess within days for sensitivity and at least six-weekly for continued indication, recording deprescribing attempts and carer views.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Memory may look better early
Attention and visuoperceptual deficits can dominate before severe episodic-memory storage failure, so a memory-weighted screen can understate early DLB disability.
Hallucinations can be calm
Well-formed visions may be neutral or even pleasant; treatment burden is not justified merely because a symptom is unusual when the person is safe and untroubled.
Sleep history reaches backwards
Dream enactment often predates cognitive and motor diagnosis by years, making an informed bed-partner history diagnostically valuable.
One-year rule is nomenclature
DLB and Parkinson disease dementia share biology; timing of dementia relative to motor onset provides consistent clinical terminology rather than a sharp mechanistic boundary.
Sensitivity can reveal disease
Unexpected profound decline after a small antipsychotic dose should prompt immediate treatment and reconsideration of an unrecognised Lewy body syndrome.
11Common pitfallsFrequent interpretation and management errors.
- 01
Calling marked short-timescale fluctuation ordinary forgetfulness misses a core diagnostic feature, while failing to exclude delirium creates equal harm.
- 02
Prescribing haloperidol reflexively for non-distressing visual hallucinations can cause severe rigidity, dysphagia, confusion and autonomic collapse.
- 03
Ruling out DLB from absent tremor ignores that bradykinesia and rigidity are sufficient parkinsonian manifestations.
- 04
Treating orthostatic falls only with physiotherapy without reviewing blood pressure and medicines leaves a major autonomic cause unaddressed.
- 05
Escalating levodopa until motor signs disappear may worsen hallucinations and confusion for limited functional gain.